News DBV gets peanut allergy therapy programme back on track Shares in DBV have shot up on phase 3 results that set up a US filing for its peanut allergy therapy. which could plug a looming hole in the market.
News Kyverna rises on stiff person syndrome data Kyverna hopes to file CAR-T therapy miv-cell for approval as the first therapy for stiff person syndrome, a rare and debilitating autoimmune disease.
News Sanofi gets double blow for MS drug tolebrutinib Shares in Sanofi have slid on a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis.
News Lilly's obesity triple pulls off 29% weight loss in trial Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.
News AC Immune says Parkinson's drug slows progression AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.
News Pfizer makes first-line case for Tukysa in breast cancer Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.